Proteínas de Transporte/genética; Contração Miocárdica/efeitos dos fármacos; Contração Miocárdica/genética; Miocárdio/metabolismo; Engenharia Tecidual; Agonistas Adrenérgicos beta/farmacologia; Animais; Cálcio/metabolismo; Bloqueadores dos Canais de Cálcio/farmacologia; Cardiomiopatia Hipertrófica/genética; Cardiomiopatia Hipertrófica/fisiopatologia; Modelos Animais de Doenças; Marcação de Genes; Espaço Intracelular/metabolismo; Isoproterenol/farmacologia; Camundongos; Camundongos Transgênicos; Transcriptoma; Verapamil/farmacologia

ATPase, Ca(2+) transporting, cardiac mRNA; Acta1; Alpha skeletal actin protein; Atp2a2; BPM; Beats per minute; Cardiac myosin-binding protein C; Cardiac myosin-binding protein C (cMyBP-C); Contraction time (spontaneous beating); Diastolic left ventricular internal diameter; Disease modeling; EC(50); EHT; EMD; EMD 57033; Engineered heart tissue; Engineered heart tissue (EHT); HCM; HET; Half maximal effective concentration; Half maximal inhibitory concentration; Heterozygous Mybpc3-targeted knock-in mice; Homozygous Mybpc3-targeted knock-in mice; Human cardiac myosin-binding protein C gene; Hypertrophic cardiomyopathy; IC(50); ISO; Induced pluripotent stem cells; Isoprenaline; KI; LVIDd; LVIDs; LVMBW; Left ventricular mass/body weight ratio; MYBPC3; Mouse cardiac myosin-binding protein C gene or mRNA; Mybpc3; Myh6; Myh7; Myofilament Ca(2+) sensitivity; Relaxation time (spontaneous beating); Slc8a1; Sodium calcium exchanger; Systolic left ventricular internal diameter; T1; T2; TTP; TTP50; TTR50; TTR90; Time to 100% of maximal twitch force; Time to 50% of maximal twitch force; Time to 50% of relaxation; Time to 90% of relaxation; cMyBP-C; iPSC; α-myosin heavy chain, α-MHC gene or mRNA; α-skAct; α-skeletal actin gene or mRNA; ß-myosin heavy chain, ß-MHC gene or mRNA